GH Research PLC (GHRS)
| Previous close | 11.19 |
| Open | 11.29 |
| Bid | 11.47 x 100 |
| Ask | 11.84 x 100 |
| Day's range | 11.29 - 12.39 |
| 52-week range | 5.05 - 14.64 |
| Volume | |
| Avg. volume | 123,283 |
| Market cap | 612.891M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.68 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 31.75 |
Globe NewswireGH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024Cash, cash equivalents, other financial assets and marketable securities of $214.0 million expected to provide cash runway into 2026 DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (
ZacksHow Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswireGH Research Reports Full Year 2023 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024Successfully completed Phase 1, dose-ranging clinical pharmacology trial of intravenous GH002 in healthy volunteersAdditional patents granted in EuropeCash, cash equivalents, other financial assets and marketable securities of $222.7 million expected to
